Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Durvalumab治疗ECOG体能状态评分为2至3分且PD-L1肿瘤高表达的初治IV期非小细胞肺癌患者（IFCT-1802 SAVIMMUNE）：一项多中心II期试验
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100908
Gounant, Valérie; Greillier, Laurent; Mascaux, Céline; Pinquie, François; Carmier, Delphine; Moreau, Lionel; Roch, Benoît; Debieuvre, Didier; Dhalluin, Xavier; Giroux-Leprieur, Etienne; Berton, Elodie; Rabeau, Audrey; Raimbourg, Judith; Dixmier, Adrien; Naltet, Charles; Khalil, Antoine; Ezzeddine, Lynn; El Hajjam, Mostafa; Langlais, Alexandra; Morin, Franck; Westeel, Virginie; Zalcman, Gérard; Duruisseaux, Michael
肺癌
肿瘤
肿瘤免疫
多发性骨髓瘤
CT-1
PD-L1
细胞生物学
